Published online Jun 16, 2021. doi: 10.12998/wjcc.v9.i17.4342
Peer-review started: February 12, 2021
First decision: March 14, 2021
Revised: March 22, 2021
Accepted: March 25, 2021
Article in press: March 25, 2021
Published online: June 16, 2021
Processing time: 102 Days and 19.1 Hours
Inflammatory bowel disease (IBD) is rare in patients with glycogen storage disease (GSD). In GSD patients, a decrease in the number of neutrophils leads to prolonged intestinal infection, leading to the formation of chronic inflammation and eventually the development of IBD. Minimally invasive surgery for patients with IBD has been proven to reduce inflammatory responses and postoperative risks and ultimately promote rapid recovery. Herein we discuss minimally invasive surgery and the perioperative management in a patient with GSD and IBD.
A 23-year-old male had GSD Ib associated with IBD-like disease for 10 years. Despite standard treatments, such as mesalazine, prednisone and adalimumab, the patient eventually developed colonic stenosis with incomplete ileus. After adequate assessment, the patient was treated with minimally invasive surgery and discharged in stable condition.
Minimally invasive surgery for patients with IBD and GSD is safe, feasible and effective.
Core Tip: With progression of inflammatory bowel disease (IBD), 70% of the patients undergo at least one surgical treatment in their lifetime, which can negatively impact physical and mental health. Glycogen storage disease is a rare genetic disease. Neutropenia in such patients leads to prolonged intestinal infections and chronic inflammation, eventually progressing to IBD. Minimally invasive surgery for IBD has the advantages of fewer injuries, less pain, more rapid recovery of gastrointestinal function and a shorter postoperative hospital stay. Specifically, minimally invasive surgery has obvious advantages for patients with glycogen storage disease and IBD due to impaired autoimmune function.